111 related articles for article (PubMed ID: 37390230)
1. Clinical characteristics and establishment of a 2-year-OS predictive model of EGFR mutation-positive patients with pleural invasion of lung adenocarcinoma.
Kong Q; Wang W; Wang Q; Yang Y; Chen G; Jiang T
Medicine (Baltimore); 2023 Jun; 102(26):e34184. PubMed ID: 37390230
[TBL] [Abstract][Full Text] [Related]
2. [Clinical Characteristics and Prognosis of 76 Lung Adenocarcinoma Patients
Harboring EGFR Mutations with Pleural Effusion at Initial Diagnosis:
A Single-center Retrospective Study].
Yin W; Zhang H; Gu Y; Yi F; Li Q; Liu Y; Yao Y; Liu Z; Cao B
Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):156-166. PubMed ID: 35340158
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between EGFR, ALK Gene Mutation and Imaging
and Pathological Features in Invasive Lung Adenocarcinoma].
Yang H; Liu Z; Wang H; Chen L; Wang J; Wen W; Xu X; Zhu Q
Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):147-155. PubMed ID: 35340157
[TBL] [Abstract][Full Text] [Related]
4. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
[TBL] [Abstract][Full Text] [Related]
5. [Correlation Analysis of Ki67 Expression and EGFR Mutation on the Risk of Recurrence and Metastasis in Postoperative Patients with Stage I Lung Adenocarcinoma].
Xu L; Guo R
Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):852-861. PubMed ID: 36617471
[TBL] [Abstract][Full Text] [Related]
6. Imaging-Based Surrogate Markers of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma: A Local Perspective.
AlGharras A; Kovacina B; Tian Z; Alexander JW; Semionov A; van Kempen LC; Sayegh K
Can Assoc Radiol J; 2020 May; 71(2):208-216. PubMed ID: 32062999
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological Features and Prognosis of Lung Adenocarcinoma Patients With K-RAS Gene Mutation.
Sun D; Liu Y; Li P; Yang P; Yu G
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):406-413. PubMed ID: 37338109
[TBL] [Abstract][Full Text] [Related]
8. [Semiquantitative parameters of
Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
10. Development and externally validate MRI-based nomogram to assess EGFR and T790M mutations in patients with metastatic lung adenocarcinoma.
Fan Y; Dong Y; Wang H; Wang H; Sun X; Wang X; Zhao P; Luo Y; Jiang X
Eur Radiol; 2022 Oct; 32(10):6739-6751. PubMed ID: 35729427
[TBL] [Abstract][Full Text] [Related]
11. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
12. Development and validation of a multivariable predictive model for EGFR gene mutation status in patients with lung adenocarcinoma.
Shi Y; Zha Q; Ye Q; Xue S; Wu H; Tang D; Qin H; Zou J
Neoplasma; 2021 Nov; 68(6):1320-1330. PubMed ID: 34689565
[TBL] [Abstract][Full Text] [Related]
13. Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma.
Nie Y; Gao W; Li N; Chen W; Wang H; Li C; Zhang H; Han P; Zhang Y; Lv X; Xu X; Liu H
World J Surg Oncol; 2017 Mar; 15(1):55. PubMed ID: 28253871
[TBL] [Abstract][Full Text] [Related]
14. EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors.
Yang J; Lee OJ; Son SM; Woo CG; Jeong Y; Yang Y; Kwon J; Lee KH; Han HS
Cancer Res Treat; 2018 Jul; 50(3):908-916. PubMed ID: 28934846
[TBL] [Abstract][Full Text] [Related]
15. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
[TBL] [Abstract][Full Text] [Related]
16. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.
Liu Y; Kim J; Qu F; Liu S; Wang H; Balagurunathan Y; Ye Z; Gillies RJ
Radiology; 2016 Jul; 280(1):271-80. PubMed ID: 26937803
[TBL] [Abstract][Full Text] [Related]
17. Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs.
Du X; Bai H; Wang Z; Daun J; Liu Z; Xu J; Chang G; Zhu Y; Wang J
Thorac Cancer; 2022 May; 13(9):1289-1298. PubMed ID: 35347870
[TBL] [Abstract][Full Text] [Related]
18. A clinically practical radiomics-clinical combined model based on PET/CT data and nomogram predicts EGFR mutation in lung adenocarcinoma.
Chang C; Zhou S; Yu H; Zhao W; Ge Y; Duan S; Wang R; Qian X; Lei B; Wang L; Liu L; Ruan M; Yan H; Sun X; Xie W
Eur Radiol; 2021 Aug; 31(8):6259-6268. PubMed ID: 33544167
[TBL] [Abstract][Full Text] [Related]
19. MET overexpression in EGFR L858R mutant treatment-naïve advanced lung adenocarcinoma correlated with poor prognosis: a real-world retrospective study.
Wang N; Zhu Y; Wu Y; Huang B; Wu J; Zhang R; Fan J; Nie X
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3219-3228. PubMed ID: 35904603
[TBL] [Abstract][Full Text] [Related]
20. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
